The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients
Cairo University
128 participants
Oct 1, 2024
INTERVENTIONAL
Conditions
Summary
This clinical trial aims to evaluate the effect of dexmedetomidine in Sepsis-Associated Acute Kidney Injury in critically ill patients by answering the following questions: 1. What is dexmedetomidine's effect on kidney functions? 2. What is the safety and efficacy of dexmedetomidine in Sepsis-Associated Acute Kidney Injury? The investigator will compare dexmedetomidine to the standard sedative. The Participant will take either dexmedetomidine or the standard sedative during their hospitalization, with follow-up of the following: 1. Vital signs including blood pressure, body temperature, respiratory rate, heart rate, and oxygen saturation. 2. Laboratory data including kidney function tests, electrolytes, complete blood count, and liver function tests. 3. An electrocardiogram will be followed to check the heart's electrical activity. 4. The level of alertness or agitation to avoid over and under-sedation. 5. The level of organ dysfunction and mortality risks. 6. Duration of mechanical ventilation. 7. Duration of hospitalization.
Eligibility
Inclusion Criteria3
- Age >21 years old
- Patients with sepsis who develop AKI within 48 hours during ICU stay
- Need for sedation due to the need for mechanical ventilation (MV) (both invasive and non- invasive) within 48 hours of AKI
Exclusion Criteria8
- Contraindications to dexmedetomidine including any of the following: severe bradycardia (heart rate (HR) < 50 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block unless a pacemaker is inserted
- Acute myocardial ischemia
- Mean arterial blood pressure < 50 mmHg despite adequate resuscitation and vasopressor therapy at the time of enrollment
- Pregnancy or lactation
- Duration of dexmedetomidine infusion < 24 hours
- Severe valvular heart disease
- Active seizures during this ICU admission requiring benzodiazepines
- Proven or suspected traumatic brain injury, intracranial hemorrhage, stroke, or spinal cord injury
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06570187